Skip to main content

Table 5 Categorisation 2: non-high FeNO and non-high blood eosinophils vs. high FeNO and high blood eosinophils

From: Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations

Characteristics Non-high FeNO and non-high blood eosinophils (n = 53) High FeNO and high blood eosinophils (n = 53) p-value
Sex
 n (% non-missing) 53 (100.0) 53 (100.0) 1.0000
 Male 48.4 (16.7) 48.2 (16.9)  
Age
 n (% non-missing) 53.0 (100.0) 53.0 (100.0) 0.9647
 Mean (SD) 48.4 (16.7) 48.2 (16.9)  
 Median (IQR) 53.0 (32.0) 53.0 (31.0)  
Age group
 n (% non-missing) 53 (100.0) 53 (100.0) 0.8655
 Under 35 14 (26.4) 14 (26.4)  
 35–65 31 (58.5) 29 (54.7)  
 66–80 8 (15.1) 10 (18.9)  
Smoking status
 n (% non-missing) 46 (86.8) 46 (86.8) 1.0000
 Non-smoker 31 (58.5) 31 (58.5)  
 Ex-smoker 4 (7.5) 4 (7.5)  
 Current smoker 11 (20.8) 11 (20.8)  
BMI
 n (% non-missing) 52 (98.1) 51 (96.2) 0.0386
 Mean (SD) 29.0 (5.9) 26.8 (5.6)  
 Median (IQR) 28.4 (8.3) 25.6 (7.1)  
FeNO
 n (% non-missing) 53 (100.0) 53 (100.0) < 0.0001
 Mean (SD) 18.6 (7.7) 57.8 (26.4)  
 Median (IQR) 20.0 (10.0) 49.0 (28.0)  
Blood eosinophil count
 n (% non-missing) 53 (100.0) 52 (98.1) < 0.0001
 Mean (SD) 0.1 (0.1) 0.5 (0.3)  
 Median (IQR) 0.1 (0.1) 0.5 (0.2)  
Active eczema diagnosisa
 n (% non-missing) 53 (100.0) 53 (100.0) 1.0000
 Yes 2 (3.8) 2 (3.8)  
Active rhinitis diagnosisa
 n (% non-missing) 53 (100.0) 53 (100.0) 0.4052
 Yes 15 (28.3) 19 (35.8)  
Eczema diagnosis
 n (% non-missing) 53 (100.0) 53 (100.0) 0.5355
 Yes 16 (30.2) 19 (35.8)  
Rhinitis diagnosis
 n (% non-missing) 53 (100.0) 53 (100.0) 0.0451
 Yes 15 (28.3) 25 (47.2)  
IHD diagnosis
 n (% non-missing) 53 (100.0) 53 (100.0) 0.5581
 Yes 1 (1.9) 2 (3.8)  
Heart failure diagnosis
 n (% non-missing) 53 (100.0) 53 (100.0)  
 Yes 0 (0.0) 0 (0.0)  
Hypertension diagnosis
 n (% non-missing) 53 (100.0) 53 (100.0) 0.0990
 Yes 15 (28.3) 8 (15.1)  
Diabetes diagnosis
 n (% non-missing) 53 (100.0) 53 (100.0) 1.0000
 Yes 3 (5.7) 3 (5.7)  
GERD active diagnosis
 n (% non-missing) 53 (100.0) 53 (100.0) 0.5063
 Yes 6 (11.3) 4 (7.5)  
Predicted peak flow
 n (% non-missing) 35 (66.0) 39 (73.6) 0.8838
 Mean (SD) 513.0 (66.7) 510.3 (69.9)  
 Median (IQR) 487.5 (122.0) 481.2 (128.0)  
ICS/LABA prescriptions per patient
 n (% non-missing) 53 (100.0) 53 (100.0) 0.2204
 Mean (SD) 3.3 (3.9) 4.0 (4.0)  
 Median (IQR) 2.0 (5.0) 3.0 (5.0)  
Mono ICS prescriptions per patient
 n (% non-missing) 53 (100.0) 53 (100.0) 0.1944
 Mean (SD) 1.3 (2.3) 0.8 (1.7)  
 Median (IQR) 0.0 (1.0) 0.0 (1.0)  
Mean daily SABA dosage (µg)
 n (% non-missing) 53 (100.0) 53 (100.0) 0.6923
 < 100 15 (28.3) 16 (30.2)  
 100–200 19 (35.8) 14 (26.4)  
 201–400 10 (18.9) 14 (26.4)  
 > 400 9 (17.0) 9 (17.0)  
ICS adherenceb
 n (% non-missing) 53 (100.0) 53 (100.0) 0.8149
 Mean (SD) 64.1 (45.3) 68.6 (72.5)  
 Median (IQR) 54.8 (54.8) 49.3 (49.3)  
  1. All values in the table are n (%) unless otherwise specified. High FeNO defined as ≥ 35 ppb; non-high FeNO < 35 ppb; high blood eosinophil count defined as ≥ 0.300 × 109 cells/L; non-high blood eosinophil count < 0.300 × 109 cells/L
  2. BMI body mass index, FeNO fractional exhaled nitric oxide, GERD gastroesophageal reflux disease, ICS inhaled corticosteroid, IHD ischaemic heart disease, IQR interquartile range, LABA long-acting β2-agonist, ppb parts per billion, SABA short-acting β2-agonist, SD standard deviation
  3. aActive denotes diagnosed in the year before FeNO reading or treated in the year before FeNO reading
  4. bMedication Possession Ratio was calculated by dividing the total of 1 day’s supply by the total number of days evaluated, multiplied by 100%. The evaluation period for all patients was 365 days in the study year